Search Results

February 2022 "Switzerland Today, InterAx Biotech is pleased to announce that Carola Weiss has joined Carola Weiss is a Senior Executive with more than 20 years of international experience in the biopharmaceutical

February 2022 "InterAx Biotech AG and Boehringer Ingelheim take first steps towards collaborating to unlock orphan targets leveraging InterAx AI driven discovery platform. first-in-class small molecule agonists for a challenging orphan GPCR for a highly relevant therapeutic need. 💊 InterAx Biotech AG discovery platform was already successfully applied in projects with biopharmaceutical companies #ai #biotech #systemsbiology #drugdiscovery #gpcr #deeptech #orphandrugs #pharma #partnerships #AI4drugdiscovery

at the GPCR-Targeted Drug Discovery Summit 2026 The meeting brings together 80+ senior leaders from biotech Sessions from InterAx Biotech, Northeastern University, and Function Therapeutics dig into this — moving Companies presenting include Skymab Biotherapeutics, Confo Therapeutics, GSK, Metaphore Biotechnologies

Every biotech founder fears the day the cash runs out. You track the burn rate. Here are the three most common sources of internal drift in early biotech teams: 1️⃣ Scientific versus Most biotech founders don’t suffer from having the wrong people. A soft skill. ✅ But in biotech, alignment is a multiplier. It’s how biotech companies move from drift to direction.

👉 Ambition is the default setting of biotech. Platforms expand. Indications multiply. without compromising strategic control and biotech fundraising credibility? into sustainable progress and stronger biotech fundraising credibility. Why Ambition Naturally Expands in Biotech Companies 👉 Ambition in biotech is data-driven. In biotech, disciplined decisions today build strategic focus, execution clarity, and stronger biotech

👉 In early-stage biotech, activity often feels like strategy. At the same time, the team is preparing for biotech fundraising. in biotech is not complexity. How Strategic Overload Weakens Biotech Fundraising Signal 👉 Biotech fundraising is not only an evaluation The difference is subtle internally. Externally, especially in biotech fundraising, it is decisive.

It is a biotech positioning problem. When biotech positioning is unclear, founders are forced to adapt their message in every interaction. The Symptoms of Unclear Biotech Positioning 👉 Most biotech founders feel that something is wrong in What Biotech Positioning Strategy Really Means 👉 Many biotech founders misunderstand positioning because Clear biotech positioning creates internal discipline.

👉 Most biotech founders  do not realize they are in trouble when the money runs out. Biotech founders rarely notice this moment because nothing visibly breaks. Why biotech founders do not see the warning signs early enough 👉 The core problem is not that biotech In early-stage biotech, progress is measured through science. Experiments advance. Data improves. This is where many biotech founders lose visibility.

👉 Strong biotech startups do not fail because the science is weak or the team is incapable. In early-stage biotech, fundraising rarely feels like a strategic threat. Fundraising rarely breaks biotech startups overnight. This is where one of the most common biotech startup fundraising mistakes takes root.   👉 Strong biotech startups do not fail at this stage because they stopped working hard.

Joanne Waldstreicher to its Board of Directors GPCR Therapeutics launches multiple myeloma trial Salipro Biotech Japan, organized by LINK-J Jounce takes the cash under amended deal with Gilead on anti-CCR8 antibody InterAx Biotech Announces the Appointment of Seasoned Pharmaceutical Executive, Dr. SLAS2023 International Conference and Exhibition (February 25 - March 1, 2023). 2nd ERNEST Training School

But here’s the uncomfortable truth: 👉 Your biotech is already running on an operating cadence you didn Operating cadence is the quiet force behind biotech momentum, the rhythm that turns intention into real The Pattern: Your “Accidental Cadence” 👉 Every biotech has a cadence. Many early-stage biotechs show the same pattern: strong scientific progress paired with an operating Strategic Takeaway Your biotech is already running on an operating cadence.

Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2023 InterAx Biotech Announces Being the Recipient of a Highly Competitive European Grant to Fund Drug Development Scientific Meeting NEW January 16 - 19, 2024 | 23rd Annual PEP Talk February 3 - 7, 2024 | SLAS2024 International

Biotech fundraising has undergone a subtle yet significant shift. Clear intellectual property builds confidence on both sides of the biotech fundraising table Why biotech Biotech fundraising rarely fails in the diligence phase itself. In modern biotech fundraising, intellectual property functions as a shortcut. In biotech fundraising, coherence builds trust.

The Quiet Drift You Don’t Feel Until It’s Too Late 👉 Every early-stage biotech reaches a moment where The Pattern: Scientific Isolation Scientific Isolation  = when a biotech’s internal activity becomes Alignment, structure, traction, visibility: these are the forces that pull a biotech out of scientific Most early biotechs think their problem is a lack of data. Attila runs focused strategy consultations for biotech founders who are ready to lead with clarity, not

Most biotech pitches don’t fail because the science is weak. A clear biotech pitch answers three key questions immediately. Strong biotech pitches don’t just inform, they align. How to Fix the Gaps 👉 Fixing your biotech pitch doesn’t require a rebrand. A strong biotech pitch isn’t about saying more.

Industry News InterAx Biotech to Apply its Leading AI and Cell Signalling Technology to Support Target Validation for a Sosei Heptares GPCR Discovery Program Salipro Biotech and DyNAbind Announce Milestone Addex Announces ADX71149 Phase 2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends

👉 In early-stage biotech , uncertainty is not an exception. It is the environment. Early-stage biotech hiring is not about perfect resumes. Why Skill-Based Hiring Breaks Down in Early-Stage Biotech Most early-stage biotech teams hire with good Early-stage biotech is none of those things. 👉 In early-stage biotech hiring, skills are selected based In early-stage biotech hiring, these moments arrive quietly.

👉 Biotech startups rarely fail all at once. This is one of the earliest reasons why biotech startups fail . This is a central reason why biotech startups fail . Order does not emerge naturally in biotech. Strategic Takeaway - Why biotech startups fail Biotech startups rarely fail because of a single mistake

neutrophils by promoting an alternative-like polarization during bacterial infection Industry News InterAx Biotech's AI platform unlocks new drug designs for diabetes, obesity, and cancer Crinetics Pharmaceuticals

Upcoming events:  Practical sessions on GPCR internalization and soluble proteins; core meetings from Allosteric Interactions When should you push the native system—and when should you partner with it? with your topic suggestions 🆕 Weekly new releases to stay ahead of the science 🧠 Content built for biotech Eric Trinquet and his team at Revvity, that moment came when they watched GPCRs internalize in native GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need

It’s a pattern we see far too often in early-stage biotech operations and startups. The 3 Golden Rules of Scientific Thinking — and Why They Break Down in Biotech Operations Leadership   In startups, waiting too long for certainty can destroy your momentum . 👉 Biotech founders often delay Scientific thinking will always be your strength, but it must be reshaped to serve your new role. 👉 As a biotech Attila runs focused strategy consultations for biotech founders  who are ready to lead with clarity,

Most biotech founders assume that failure comes from making the wrong call. A flawed experiment. A missed partnership. 👉 Biotech startup failure is usually imagined as a moment where something clearly In reality, many biotech startups drift into trouble without ever making a single decision that looks Why This Type of Biotech Startup Failure Is Hard to Detect 👉 What makes this form of biotech startup This is where biotech startup failure becomes operationally real .

that closed door lit the fuse for a career that would reimagine GPCR therapeutics — and lead to two biotech What followed was a scientific journey that now spans two biotech startups, and a bold reimagining of It was investor rejections, endless slide decks, and the steep learning curve of biotech business. Launching Blue was Ajay’s first hands-on experience with biotech entrepreneurship. Lessons From the Front Lines of Biotech Ajay’s experience in both early-stage biotech and academic science

July 2022 "G.CLIPS biotech is 2 years old today🎂. Looking forward for more 🎊 #team #grateful #biotech #work #birthdaycelebration" Read more at the source

The Gaps They Already See 👉 As a biotech founder, it’s easy to mistake volume for readiness . Clarity, not complexity, is what makes approval possible, and biotech sustainable. The Illusion of Readiness 👉 Many biotech founders walk into a pre-IND meeting with quiet confidence What the FDA Is Actually Optimizing For 👉 Biotech teams often treat the FDA like an evaluator. Reverse Engineering Your Path to FDA Approval Most biotech development plans are built forward : start

We’ve also highlighted the latest research on non-canonical internalization mechanisms of mGlu receptors GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who discovery, pharmacology, antagonism, competitive, non-competitive, Terry's Corner, Yamina's Corner, biotech development, pharmaceutical, scientific career Hashtags: #DrGPCR #GPCR #DrugDiscovery #Pharmacology #Biotech

October 2022 Intermolecular Interactions in G Protein-Coupled Receptor Allosteric Sites at the Membrane Interface from Molecular Dynamics Simulations and Quantum Chemical Calculations "Allosteric modulators binding location that raises many questions about the ligand interactions and stability, the binding In this work, we analyze interactions in the allosteric sites of the PAR2, C5aR1, and GCGR receptors The availability of polar atoms for interactions in such cavities can be assessed by water molecules

session, you’ll gain: ✅Clarity on Definitions:  What truly distinguishes orthosteric from allosteric interactions Allosteric Interactions Still Matter Orthosteric and allosteric interactions have been in pharmacology Recognizing how your ligand interacts with the receptor lets you predict safety margins, dose–response with your topic suggestions 🆕 Weekly new releases to stay ahead of the science 🧠 Content built for biotech If your team is still treating orthosteric and allosteric interactions as interchangeable, you’re leaving

It was about internal ignition. She moved from “What am I supposed to do?” She went from reluctant intern to global researcher shaping how we understand GPCR spatial signaling. For innovators and biotech strategists, stories like Michelle’s reveal how scientific leadership emerges For biotech innovators, those sparks are the future workforce and idea engines.

the architect behind nearly all of Exscientia's partnerships and collaborations across pharma and #biotech⁠